225 related articles for article (PubMed ID: 29454590)
1. Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.
Benidir T; Hersey K; Finelli A; Hamilton R; Joshua AM; Kulkarni G; Zlotta A; Fleshner N
Urol Oncol; 2018 May; 36(5):240.e13-240.e20. PubMed ID: 29454590
[TBL] [Abstract][Full Text] [Related]
2. Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation.
Rentz AM; Mansukhani SG; Liu J; Lloyd AJ; Heidenreich S; Matza LS; Dawson NA; Shore N; Freedland SJ
Urol Oncol; 2021 Jun; 39(6):367.e7-367.e17. PubMed ID: 33736976
[TBL] [Abstract][Full Text] [Related]
3. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
[TBL] [Abstract][Full Text] [Related]
4. Should we involve patients more actively? Perspectives of the multidisciplinary team on shared decision-making for older patients with metastatic castration-resistant prostate cancer.
de Angst IB; Kil PJM; Bangma CH; Takkenberg JJM
J Geriatr Oncol; 2019 Jul; 10(4):653-658. PubMed ID: 30639265
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review.
Grochtdreis T; König HH; Dobruschkin A; von Amsberg G; Dams J
PLoS One; 2018; 13(12):e0208063. PubMed ID: 30517165
[TBL] [Abstract][Full Text] [Related]
6. Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience.
Afshar M; Evison F; James ND; Patel P
Urol Oncol; 2015 Aug; 33(8):338.e1-7. PubMed ID: 26059077
[TBL] [Abstract][Full Text] [Related]
7. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
Anantharaman A; Small EJ
Expert Rev Anticancer Ther; 2017 Jul; 17(7):625-633. PubMed ID: 28532278
[TBL] [Abstract][Full Text] [Related]
8. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.
Mukherji D; Omlin A; Pezaro C; Shamseddine A; de Bono J
Cancer Metastasis Rev; 2014 Sep; 33(2-3):555-66. PubMed ID: 24452758
[TBL] [Abstract][Full Text] [Related]
9. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
10. Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians.
Sureka SK; Maheshwari R; Agnihotri S; Mitash N; Ahmad S; Mandhani A
Indian J Med Res; 2016 May; 143(Supplement):S68-S73. PubMed ID: 27748280
[TBL] [Abstract][Full Text] [Related]
11. Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment.
Uemura H; Matsubara N; Kimura G; Yamaguchi A; Ledesma DA; DiBonaventura M; Mohamed AF; Basurto E; McKinnon I; Wang E; Concialdi K; Narimatsu A; Aitoku Y
BMC Urol; 2016 Nov; 16(1):63. PubMed ID: 27814714
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
[TBL] [Abstract][Full Text] [Related]
13. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
[TBL] [Abstract][Full Text] [Related]
14. Management of patients with castration-resistant prostate cancer (CRPC): results of an Italian survey using the delphi method.
Terrone C; Berruti A; Papotti M; Vavassori V; Sciarra A
Tumori; 2016 Oct; 102(5):514-520. PubMed ID: 26166221
[TBL] [Abstract][Full Text] [Related]
15. Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.
Hernandez RK; Cetin K; Pirolli M; Quigley J; Quach D; Smith P; Stryker S; Liede A
Can J Urol; 2015 Aug; 22(4):7858-64. PubMed ID: 26267023
[TBL] [Abstract][Full Text] [Related]
16. A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer.
Heck MM; Thalgott M; Schmid SC; Oh WK; Gong Y; Wang L; Zhu J; Seitz AK; Porst D; Höppner M; Retz M; Gschwend JE; Nawroth R
Prostate; 2016 Sep; 76(13):1160-8. PubMed ID: 27198487
[TBL] [Abstract][Full Text] [Related]
17. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
18. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
[TBL] [Abstract][Full Text] [Related]
19. A urologic oncology roundtable discussion: issues to consider in choosing treatment for metastatic castration-resistant prostate cancer.
Taplin ME; Berry WR; Casey AM; Aslo A
Hosp Pract (1995); 2013; 41(4):81-2. PubMed ID: 24145593
[TBL] [Abstract][Full Text] [Related]
20. A urologic oncology roundtable discussion: the role of disease monitoring in treatment decision-making for patients with metastatic castration-resistant prostate cancer.
Shore ND; Concepcion R; Barocas DA
Hosp Pract (1995); 2013; 41(4):78-80. PubMed ID: 24145592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]